USA – Viz.ai, a health-tech startup backed by artificial intelligence, announced a US$100 million Series D funding round, bringing its total valuation to US$1.2 billion.
The round was led by Tiger Global and Insight Partners, with participation from Scale Ventures, Kleiner Perkins, Threshold, GV, Sozo Ventures, CRV, and Susa.
This announcement comes about a year after the company closed its US$71 million Series C round. As of today, the company has received more than US$250 million in venture capital.
Viz.ai created a care-coordination tool to assist clinical teams in sharing images and detecting potential diseases.
The product’s AI tool can help triage clinical images and detect strokes, allowing care teams to prioritize patients.
At the moment, it offers AI detection products for aortic diseases, pulmonary embolism, and cerebral aneurysms. The company stated that it is awaiting 510(k) approval for subdural hematoma.
Specialists who use the system can access a mobile view of scans, allowing them to zoom in and out of images and visualize the scan in 3D.
The new funds, according to the company, will help fuel the company’s growth. The funds will also be used to expand the Viz Platform’s disease-triaging capabilities.
Dr. Chris Mansi, Viz.ai cofounder and CEO, said in a statement, “We will continue to invest heavily in cutting-edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates and enhance workflows across the entire hub and spoke health system.”
“More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”
The company, which was founded in 2016, received an FDA De Novo in 2018 for its Viz.ai Contact, a clinical decision-support tool that analyzes CT scans and flags a detected stroke.
The company has continued to collaborate with the FDA on new algorithms. Most recently, the company received FDA 510(k) clearance in February for its algorithm designed to detect cerebral aneurysms.
Several digital health companies are active in the stroke-care space. For example, in 2021, the Indian startup Qure.ai announced the launch of a new stroke management platform that allows providers to diagnose and make decisions remotely.
Qure.ai recently raised US$40 million in a funding round led by Novo Holdings and HealthQuad, to expand and strengthen its global presence, particularly in the United States and Europe, as well as to accelerate product development for critical care and community diagnostics.
MindRhythm, a stroke-triaging company, also launched a multicenter clinical trial in 2021 to test the efficacy of its stroke-detecting technology.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
